Taurine treatment inhibits CaMKII activity and modulates the presence of calbindin D28k, calretinin, and parvalbumin in the brain

Journal of Neuroscience Research

Volumn 88, Issue 1, 2010, Pages 136-142

  Junyent, Fèlix ^a   Romero, R ^a   De Lemos, L ^a   Utrera, J ^a   Camins, A ^a   Pallas M ^a   Auladell, C ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Calbindin D28k; Calretinin; CAMKII; Parvalbumin; Taurine

Indexed keywords

CALBINDIN; CALCIUM; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALPAIN; CALRETININ; PARVALBUMIN; PROTEINASE; TAURINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN; CALCIUM HOMEOSTASIS; CALCIUM SIGNALING; CONTROLLED STUDY; CORPUS STRIATUM; HIPPOCAMPUS; IMMUNOREACTIVITY; IN VIVO STUDY; MALE; MOUSE; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CALPAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; MICE; NEURONS; PARVALBUMINS; SPECTROMETRY, FLUORESCENCE; STATISTICS, NONPARAMETRIC; TAURINE; TIME FACTORS;

EID: 73949111610     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22192     Document Type: Article

References (49)

1. Baimbridge KG, Celio MR, Rogers JH. 1992. Calcium-binding proteins in the nervous system. Trends Neurosci 15:303-308.
2. Birdsall TC. 1998. Therapeutic applications of taurine. Altern Med Rev 3:128-136.
3. Bouilleret V, Schwaller B, Schurmans S, Celio MR, Fritschy JM. 2000. Neurodegenerative and morphogenic changes in a mouse model of temporal lobe epilepsy do not depend on the expression of the calcium-binding proteins parvalbumin, calbindin, or calretinin. Neuroscience 97:47-58.
4. Cano-Abad MF, Villarroya M, García AG, Gabilan NH, López MG. 2001. Calcium entry through L-type calcium channels causes mitochondrial disruption and chromaffin cell death. J Biol Chem 276: 39695-39704.
5. Chen WQ, Jin H, Nguyen M, Carr J, Lee YJ, Hsu CC, Faiman MD, Schloss JV, Wu JY. 2001. Role of taurine in regulation of intracellular calcium level and neuroprotective function in cultured neurons. J Neurosci Res 66:612-619.
6. Dopico JG, Gonzalez-Hernandez T, Perez IM, Garcia IG, Abril AM, Inchausti JO, Rodriguez Diaz M. 2006. Glycine release in the substantia nigra: interaction with glutamate and GABA. Neuropharmacology 50:548-557.
7. El Idrissi A. 2008. Taurine increases mitochondrial buffering of calcium: role in neuroprotection. Amino Acids 34:321-328.
8. El Idrissi A, Trenkner E. 1999. Growth factors and taurine protect against excitotoxicity by stabilizing calcium homeostasis and energy metabolism. J Neurosci 19:9459-9468.
9. El Idrissi A, Trenkner E. 2003. Taurine regulates mitochondrial calcium homeostasis. Adv Exp Med Biol 526:527-536.
10. Fan W, Agarwal N, Cooper NG. 2006. The role of CaMKII in BDNFmediated neuroprotection of retinal ganglion cells (RGC-5). Brain Res 1067:48-57.
11. Figueredo-Cardenas G, Harris CL, Anderson KD, Reiner A. 1998. Relative resistance of striatal neurons containing calbindin or parvalbumin to quinolinic acid-mediated excitotoxicity compared with other striatal neuron types. Exp Neurol 149:356-372.
12. French ED, Vezzani A, Whetsell WO, Schwarcz R. 1986. Anti-excitotoxic actions of taurine in the rat hippocampus studied in vivo and in vitro. Adv Exp Med Biol 203:349-362.
13. German DC, Manaye KF, Sonsalla PK, Brooks BA. 1992. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann N Y Acad Sci 648:42-62.
14. Gupta RC, Win T, Bittner S. 2005. Taurine analogues; a new class of therapeutics: retrospect and prospects. Curr Med Chem 12:2021-2039.
15. Hendil KB, Hoffmann EK. 1974. Cell volume regulation in Ehrlich ascites tumor cells. J Cell Physiol 84:115-125.
16. Hontanilla B, Parent A, de las Heras S, Gimenez-Amaya JM. 1998. Distribution of calbindin D-28k and parvalbumin neurons and fibers in the rat basal ganglia. Brain Res Bull 47:107-116.
17. Huxtable RJ. 1989. Taurine in the central nervous system and the mammalian actions of taurine. Prog Neurobiol 32:471-533.
18. Huxtable RJ. 1992. Physiological actions of taurine. Physiol Rev 72:101-163.
19. Idrizbegovic E, Canlon B, Bross LS, Willott JF, Bogdanovic N. 2001. The total number of neurons and calcium binding protein positive neurons during aging in the cochlear nucleus of CBA/CaJ mice: a quantitative study. Hear Res 158:102-115.
20. Isaacs KR, Wolpoe ME, Jacobowitz DM. 2000. Vulnerability to calcium-induced neurotoxicity in cultured neurons expressing calretinin. Exp Neurol 163:311-323.
21. Izumi K, Butterworth RF, Barbeau A. 1977. Effect of taurine on calcium binding to microsomes isolated from rat cerebral cortex. Life Sci 20:943-950.
22. Jacobson I, Hamberger A. 1985. Kainic acid-induced changes of extracellular amino acid levels, evoked potentials and EEG activity in the rabbit olfactory bulb. Brain Res 348:289-296.
23. Junyent F, Utrera J, Romero R, Palla̧s M, Camins A, Duque D, Auladell C. 2009. Prevention of epilepsy by taurine treatments in mice experimental model. J Neurosci Res 87:1500-1508.
24. Law RO. 1998. The role of taurine in the regulation of brain cell volume in chronically hyponatraemic rats. Neurochem Int 33:467-472.
25. Lehmann A, Hagberg H, Jacobson I, Hamberger A. 1985. Effects of status epilepticus on extracellular amino acids in the hippocampus. Brain Res 359:147-151.
26. Lerma J, Herranz AS, Herreras O, Abraira V, Martin del Rio R. 1986. In vivo determination of extracellular concentration of amino acids in the rat hippocampus. A method based on brain dialysis and computerized analysis. Brain Res 384:145-155.
27. Lin CH, Chen PS, Gean PW. 2008. Glutamate preconditioning prevents neuronal death induced by combined oxygen-glucose deprivation in cultured cortical neurons. Eur J Pharmacol 589:85-93.
28. Lin KF, Chang RC, Suen KC, So KF, Hugon J. 2004. Modulation of calcium/calmodulin kinase-II provides partial neuroprotection against beta-amyloid peptide toxicity. Eur J Neurosci 19:2047-2055.
29. Lukas W, Jones KA. 1994. Cortical neurons containing calretinin are selectively resistant to calcium overload and excitotoxicity in vitro. Neuroscience 61:307-316.
30. McNamara JO. 1992. The neurobiological basis of epilepsy. Trends Neurosci 15:357-359.
31. Meyer FB. 1989. Calcium, neuronal hyperexcitability and ischemic injury. Brain Res Brain Res Rev 14:227-243.
32. Muramatsu M, Kakita K, Nakagawa K, Kuriyama K. 1978. A modulating role of taurine on release of acetylcholine and norepinephrine from neuronal tissues. Jpn J Pharmacol 28:259-268.
33. Nagelhus EA, Lehmann A, Ottersen OP. 1993. Neuronal-glial exchange of taurine during hypo-osmotic stress: a combined immunocytochemical and biochemical analysis in rat cerebellar cortex. Neuroscience 54:615-631.
34. Narita M, Kuzumaki N, Miyatake M, Sato F, Wachi H, Seyama Y, Suzuki T. 2006. Role of delta-opioid receptor function in neurogenesis and neuroprotection. J Neurochem 97:1494-505.
35. Palkovits M, Elekes I, Lang T, Patthy A. 1986. Taurine levels in discrete brain nuclei of rats. J Neurochem 47:1333-1335.
36. 2+ sequestration by taurine. Biochem Pharmacol 58:1123-1131.
37. Pasantes-Morales H, Franco R, Torres-Marquez ME, Hernandez-Fonseca K, Ortega A. 2000. Amino acid osmolytes in regulatory volume decrease and isovolumetric regulation in brain cells: contribution and mechanisms. Cell Physiol Biochem 10:361-370.
38. Rogers JH, Resibois A. 1992. Calretinin and calbindin-D28k in rat brain: patterns of partial co-localization. Neuroscience 51:843-865.
39. Schurr A, Tseng MT, West CA, Rigor BM. 1987. Taurine improves the recovery of neuronal function following cerebral hypoxia: an in vitro study. Life Sci 40:2059-2066.
40. Solis JM, Herranz AS, Herreras O, Lerma J, Martin del Rio R. 1988. Does taurine act as an osmoregulatory substance in the rat brain? Neurosci Lett 91:53-58.
41. Speckmann EJ, Walden J, Bingmann D. 1989. Functional implication of calcium ions in epileptic seizures. Antiepileptic effects of organic calcium antagonists. Arzneimittelforschung 39:149-156.
42. Sun M, Xu C. 2008. Neuroprotective mechanism of taurine due to upregulating calpastatin and down-regulating calpain and caspase-3 during focal cerebral ischemia. Cell Mol Neurobiol 28:593-611
43. Trenkner E. 1990. The role of taurine and glutamate during early postnatal cerebellar development of normal and weaver mutant mice. Adv Exp Med Biol 268:239-244.
44. Tsuboi K, Kimber TA, Shults CW. 2000. Calretinin-containing axons and neurons are resistant to an intrastriatal 6-hydroxydopamine lesion. Brain Res 866:55-64.
45. Vosler PS, Brennan CS, Chen J. 2008. Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. Mol Neurobiol 38: 78-100.
46. Wade JV, Samson FE, Nelson SR, Pazdernik TL. 1987. Changes in extracellular amino acids during soman- and kainic acid-induced seizures. J Neurochem 49:645-650.
47. Wright CE, Tallan HH, Lin YY, Gaull GE. 1986. Taurine: biological update. Annu Rev Biochem 55:427-453.
48. Wu H, Jin Y, Wei J, Jin H, Sha D, Wu JY. 2005. Mode of action of taurine as a neuroprotector. Brain Res 1038:123-131.
49. Wu JY, Lin CT, Johansen FF, Liu JW. 1994. Taurine neurons in rat hippocampal formation are relatively inert to cerebral ischemia. Adv Exp Med Biol 359:289-298.